Abstract

BackgroundThere is a lack of consensus concerning the definition of re-irradiation and re-irradiation volumes in head and neck cancer (HNC). The aim of the present study is to introduce a more strict definition of the re-irradiated volume that might better predict the risk of serious side-effects from treatment.MethodsFifty-four consecutive patients re-irradiated for HNC cancer were retrospectively analysed. CT images were deformably registered and the dose distributions accumulated after conversion to EQD2. Patients with a cumulative dose of ≥100 Gy in the overlapping volume (V100) were included in the study. Survival data and radiation-related acute and late toxicities were recorded.ResultsThe overall survival of all included patients at 2 and 5 years was 42.6 and 27.3% respectively and the progression free survival at 2 and 5 years was 32.5 and 28.5% respectively. The overall rate of any event of severe (grade ≥ 3) acute and late toxicity was 26 and 51%, respectively. We found that severe acute toxicity was more common in patients who had a larger overlapping volume (V100 > mean) where 43% of the patients experienced grade ≥ 3 acute toxicity, compared to the patients with smaller overlapping volumes (V100 < mean) where only 11% had severe toxicity (p = 0.02). The seemingly high rates of late toxicity in the present study could be due to the use of a more strict definition of re-irradiation. In previous studies also patients with low dose overlap are included and our results imply that there is a risk that previous studies might have overestimated the risk-benefit ratio in re-irradiation of HNC.ConclusionsOur study describes the outcome of a patient material where a more strict definition of the re-irradiated volume is used. With this definition, which could better describe the volume of highest risk for serious complications, we found that larger such overlapping volumes result in an increase in severe acute side-effects. A clear definition of re-irradiation and re-irradiation volumes is of utmost importance for future studies of HNC to make results from different studies comparable.

Highlights

  • There is a lack of consensus concerning the definition of re-irradiation and re-irradiation volumes in head and neck cancer (HNC)

  • Phan et al conducted a study of re-irradiation with proton therapy of 60 HNC patients and this study showed that there was a significant association between a clinical target volume ≥ 50 cm3 and acute as well as late grade ≥ 3 toxicities [29]

  • The definition of re-irradiation and re-irradiation volumes is crucial in future studies in re-irradiation of HNC and a necessity to make results from different studies comparable

Read more

Summary

Introduction

There is a lack of consensus concerning the definition of re-irradiation and re-irradiation volumes in head and neck cancer (HNC). Local recurrence is the predominant pattern of failure after treatment of advanced head and neck cancer (HNC) [1]. The treatment method of choice is surgical resection [2], but for many patients, surgery is not possible due to unresectable tumour or co-morbidity. These patients may be offered palliative chemotherapy, associated with a median progression-free survival (PFS) of 3–4 months and a median overall survival (OS) of 6–10 months [3,4,5]. Immunotherapy can offer long-lasting remission for some patients, without the toxicity of chemotherapy, but only a limited group of patients with recurrent HNC benefit from immunotherapy and the knowledge regarding predictive factors in this group is still limited [6, 7]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call